2010
Infectious Disease Comorbidities Adversely Affecting Substance Users With HIV: Hepatitis C and Tuberculosis
Friedland G. Infectious Disease Comorbidities Adversely Affecting Substance Users With HIV: Hepatitis C and Tuberculosis. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2010, 55: s37-s42. PMID: 21045598, PMCID: PMC4505738, DOI: 10.1097/qai.0b013e3181f9c0b6.Peer-Reviewed Original ResearchConceptsHepatitis CDrug interactionsDrug usersDrug useActive screening programsSpecial clinical challengeIsoniazid preventive therapySubstance abusersInjection drug usePharmacodynamic drug interactionsDrug-resistant organismsTreatment of tuberculosisInfectious disease comorbiditiesHIV/AIDSPreventive therapyTreatment initiationComorbid conditionsMedication adherenceHIV pandemicScreening programClinical challengeClinician expertiseTherapeutic successClinical consequencesInfection controlTreatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs
Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. The Lancet 2010, 376: 367-387. PMID: 20650518, PMCID: PMC4855280, DOI: 10.1016/s0140-6736(10)60829-x.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAnti-HIV AgentsAntipsychotic AgentsAntitubercular AgentsAntiviral AgentsBacterial InfectionsComorbidityCriminal LawDrug InteractionsDrug Resistance, BacterialEvidence-Based MedicineHepatitis, Viral, HumanHIV InfectionsHumansMedication AdherenceMental DisordersNarcoticsPrisonersSubstance-Related DisordersTuberculosisConceptsSubstance use disordersDrug usersAntiretroviral therapyViral hepatitisHIV treatmentHealth of HIVPharmacokinetic drug interactionsSubstance use comorbiditiesMedication-assisted therapyEvidence-based treatmentsDrug-resistant strainsHealth-related outcomesHealth service deliveryInfectious complicationsMultiple comorbiditiesHIV infectionPsychiatric comorbidityPoor adherenceClinical managementCardiovascular diseaseInadequate prescriptionCongregate settingsDrug interactionsComorbiditiesHIV
2008
Attitudes toward needle-sharing and HIV transmission risk behavior among HIV+ injection drug users in clinical care
Norton WE, Amico KR, Fisher WA, Copenhaver MM, Kozal MJ, Cornman DH, Friedland G, Fisher JD. Attitudes toward needle-sharing and HIV transmission risk behavior among HIV+ injection drug users in clinical care. AIDS Care 2008, 20: 462-469. PMID: 18449824, DOI: 10.1080/09540120701867081.Peer-Reviewed Original ResearchConceptsHIV-positive injection drug usersInjection drug usersRisk reduction interventionsClinical careDrug usersInjection drug use accountsHIV transmission risk behaviorsIncident HIV infectionTransmission risk behaviorsDrug-resistant HIVClinical care settingsSpread of HIVLogistic regression modelsAntiretroviral therapyHIV infectionHIV transmissionCare settingsRisk behaviorsClinical settingPast monthNegative attitudesSignificant correlatesHIVInterventionConsiderable proportion
2007
Superiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial
Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial. Clinical Infectious Diseases 2007, 45: 770-778. PMID: 17712763, PMCID: PMC2693907, DOI: 10.1086/521166.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsSelf-administered therapyT-lymphocyte countsDrug usersAntiretroviral therapyLymphocyte countRNA levelsPrimary outcomeProportion of patientsGreater mean reductionHIV treatment programsLog10 copies/Human immunodeficiency virusCopies/mLDAART groupVirologic outcomesSecondary outcomesControlled TrialsImmunodeficiency virusPoor adherenceTreatment adherenceEntry criteriaTreat approachCopies/Mean change
2005
HIV Drug Resistance and HIV Transmission Risk Behaviors Among Active Injection Drug Users
Kozal MJ, Amico KR, Chiarella J, Cornman D, Fisher W, Fisher J, Friedland G. HIV Drug Resistance and HIV Transmission Risk Behaviors Among Active Injection Drug Users. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2005, 40: 106-109. PMID: 16123691, DOI: 10.1097/01.qai.0000159666.95455.d2.Peer-Reviewed Original ResearchConceptsInjection drug usersDrug-resistant HIVHIV drug resistanceResistant HIVDrug usersRisk behaviorsClinical careActive injection drug usersDrug resistanceHIV transmission risk behaviorsTransmission risk behaviorsInjection risk behaviorsRetrospective studyInjection drugsHIVPrevious monthCareSubstantial numberMultiple partnersDrugsSmall proportionPatientsProportionNeedleMonths
2004
Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication
Altice FL, Mezger JA, Hodges J, Bruce RD, Marinovich A, Walton M, Springer SA, Friedland GH. Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication. Clinical Infectious Diseases 2004, 38: s376-s387. PMID: 15156426, DOI: 10.1086/421400.Peer-Reviewed Original ResearchConceptsMedian HIV-1 RNA loadDrug usersHIV-1 RNA loadMost subjectsHuman immunodeficiency virusSelf-administered therapySyringe exchange programsMedian CD4Antiretroviral therapyDaily regimensMedical comorbiditiesImmunodeficiency virusEmergency departmentRNA loadMethadone clinicsMedication administrationOwn medicationsCopies/Major depressionMedical appointmentsTherapy interventionCell countDAARTCells/Medical servicesDrug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Nelfinavir
McCance‐Katz E, Rainey PM, Smith P, Morse G, Friedland G, Gourevitch M, Jatlow P. Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Nelfinavir. American Journal On Addictions 2004, 13: 163-180. PMID: 15204667, DOI: 10.1080/10550490490436037.Peer-Reviewed Original ResearchConceptsDrug interactionsMetabolite exposureClinical pharmacology studiesInjection drug usersNelfinavir concentrationsOpiate medicationsOpiate therapyMethadone exposureAntiretroviral medicationsHIV outcomesDay study periodPharmacology studiesDrug usersMethadoneNelfinavirLAAMStudy periodMedicationsMinimal overall changeProtease inhibitorsExposureToxicityOverall changeAntiretroviralsOpioids
2003
Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users
Altice FL, Springer S, Buitrago M, Hunt DP, Friedland GH. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. Journal Of Urban Health 2003, 80: 416-427. PMID: 12930880, PMCID: PMC3455979, DOI: 10.1093/jurban/jtg053.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusNondetectable viral loadCD4 lymphocyte countDrug treatmentDrug usersLymphocyte countViral loadHIV therapyBaseline HIV-1 RNA levelsNeedle exchangeHealth servicesHIV-1 RNA levelsPilot studyPotent antiretroviral combinationUtilization of HAARTActive antiretroviral therapyAntiretroviral therapy regimensHIV-1 RNACommunity-based health interventionsAdverse side effectsActive drug usersFormal drug treatmentImmunodeficiency syndrome (AIDS) incidenceSmall pilot studyActive heroin injectorsThe Protease Inhibitor Lopinavir-Ritonavir May Produce Opiate Withdrawal in Methadone-Maintained Patients
McCance-Katz EF, Rainey PM, Friedland G, Jatlow P. The Protease Inhibitor Lopinavir-Ritonavir May Produce Opiate Withdrawal in Methadone-Maintained Patients. Clinical Infectious Diseases 2003, 37: 476-482. PMID: 12905130, DOI: 10.1086/376907.Peer-Reviewed Original ResearchConceptsLopinavir-ritonavirMethadone metabolismSubstance abuse pharmacotherapyOpiate withdrawal symptomsInjection drug usersConcentration-time curveMethadone areaMethadone dosesHIV diseaseMethadone concentrationsOral clearancePharmacodynamic interactionsWithdrawal symptomsOpiate withdrawalClinical monitoringDrug usersSame dosageRitonavirPotent inducerPatientsMethadoneProtease inhibitorsSignificant reductionR formulationTreatment
2002
Increasing drug users’ adherence to HIV treatment: results of a peer-driven intervention feasibility study
Broadhead RS, Heckathorn DD, Altice FL, van Hulst Y, Carbone M, Friedland GH, O’Connor P, Selwyn PA. Increasing drug users’ adherence to HIV treatment: results of a peer-driven intervention feasibility study. Social Science & Medicine 2002, 55: 235-246. PMID: 12144138, DOI: 10.1016/s0277-9536(01)00167-8.Peer-Reviewed Original ResearchConceptsActive drug usersDrug users' adherenceDrug usersDrug treatmentMedical carePrimary careIntervention feasibility studySocial support structuresHealth advocatesUser adherenceTreatment program staffPeer-driven interventionHIV diseaseHIV infectionPatient adherenceSix-month studyHIV treatmentPhysician referralClinical appointmentsHIV therapeuticsCarePositive behavioral changesAdherencePeer pressureTreatment
2001
Effect of Opioid Dependence Pharmacotherapies on Zidovudine Disposition
McCance‐Katz E, Rainey P, Friedland G, Kosten T, Jatlow P. Effect of Opioid Dependence Pharmacotherapies on Zidovudine Disposition. American Journal On Addictions 2001, 10: 296-307. PMID: 11783744, DOI: 10.1111/j.1521-0391.2001.tb00519.x.Peer-Reviewed Original ResearchConceptsOpioid-dependence pharmacotherapyHuman immunodeficiency virusZDV toxicityActive antiretroviral therapyInjection drug usersTime-concentration curveZDV pharmacokineticsZidovudine dispositionAntiretroviral therapyOpioid pharmacotherapyDose adjustmentOpioid dependenceImmunodeficiency virusZDV concentrationsControl subjectsMethadone maintenanceDrug usersPharmacotherapyZidovudineBuprenorphineNaltrexoneSignificant differencesLAAMToxicitySubjectsTrust and the Acceptance of and Adherence to Antiretroviral Therapy
Altice F, Mostashari F, Friedland G. Trust and the Acceptance of and Adherence to Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 47-58. DOI: 10.1097/00126334-200109010-00008.Peer-Reviewed Original ResearchInjection drug usersAntiretroviral therapyPotent new therapyStandardized chart reviewSocial isolationDrugs of abuseAntiretroviral regimenHIV clinicChart reviewHIV infectionHIV medicationsObserved therapyCorrelates of acceptanceHealth beliefsClinical informationHealth locusNew therapiesSide effectsPharmacy reviewDrug usersHealth statusInfected prisonersAIDS incidenceTherapyTherapeutic agentsTrust and the Acceptance of and Adherence to Antiretroviral Therapy.
Altice FL, Mostashari F, Friedland GH. Trust and the Acceptance of and Adherence to Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 47. PMID: 11579277, DOI: 10.1097/00042560-200109010-00008.Peer-Reviewed Original ResearchConceptsInjection drug usersAntiretroviral therapyPotent new therapyStandardized chart reviewSocial isolationDrugs of abuseAntiretroviral regimenHIV clinicChart reviewHIV infectionHIV medicationsObserved therapyCorrelates of acceptanceHealth beliefsClinical informationHealth locusNew therapiesSide effectsPharmacy reviewDrug usersHealth statusInfected prisonersAIDS incidenceTherapyTherapeutic agents
2000
Interaction of Methadone with Didanosine and Stavudine
Rainey P, Friedland G, McCanceKatz E, Andrews L, Mitchell S, Charles C, Jatlow P. Interaction of Methadone with Didanosine and Stavudine. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 24: 241-248. PMID: 10969348, DOI: 10.1097/00126334-200007010-00007.Peer-Reviewed Original ResearchConceptsD4TMethadone therapyMore nucleoside analoguesStable methadone therapyActive antiretroviral therapyEffects of methadonePeak drug concentrationInjection drug usersInteraction of methadoneOpiate-dependent injection drug usersCurrent HAART regimensTime-concentration curveExtrapolated AUCMethadone dispositionAntiretroviral therapyHAART regimensDosing intervalTrough levelsMethadone treatmentHistorical controlsLarge dosesStudy subjectsDrug usersMethadoneDrug concentrationsInteraction of Methadone with Didanosine and Stavudine
Rainey P, Friedland G, McCance-Katz E, Andrews L, Mitchell S, Charles C, Jatlow P. Interaction of Methadone with Didanosine and Stavudine. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 24: 241-248. DOI: 10.1097/00042560-200007010-00008.Peer-Reviewed Original ResearchConceptsD4TMethadone therapyMore nucleoside analoguesStable methadone therapyActive antiretroviral therapyEffects of methadonePeak drug concentrationInjection drug usersInteraction of methadoneOpiate-dependent injection drug usersCurrent HAART regimensTime-concentration curveExtrapolated AUCMethadone dispositionAntiretroviral therapyHAART regimensDosing intervalTrough levelsMethadone treatmentHistorical controlsLarge dosesStudy subjectsDrug usersMethadoneDrug concentrations
1998
Methadone Effects on Zidovudine Disposition (AIDS Clinical Trials Group 262)
McCanceKatz E, Rainey P, Jatlow P, Friedland G. Methadone Effects on Zidovudine Disposition (AIDS Clinical Trials Group 262). JAIDS Journal Of Acquired Immune Deficiency Syndromes 1998, 18: 435-443. PMID: 9715839, DOI: 10.1097/00042560-199808150-00004.Peer-Reviewed Original ResearchConceptsInjection drug usersMethadone treatmentChronic methadone treatmentMethadone-maintained patientsHeroin-addicted patientsMethadone effectsZDV doseZDV exposureZDV pharmacokineticsZDV treatmentZidovudine dispositionZidovudine therapyHIV diseaseMethadone levelsPharmacokinetic interactionsTherapeutic rangeRenal clearanceToxicity surveillanceSide effectsDrug usersDrug efficacyZDVClearanceAUCPatients
1996
A prospective study of syphilis and HIV infection among injection drug users receiving methadone in the Bronx, NY.
Gourevitch M, Hartel D, Schoenbaum E, Selwyn P, Davenny K, Friedland G, Klein R. A prospective study of syphilis and HIV infection among injection drug users receiving methadone in the Bronx, NY. American Journal Of Public Health 1996, 86: 1112-5. PMID: 8712270, PMCID: PMC1380622, DOI: 10.2105/ajph.86.8_pt_1.1112.Peer-Reviewed Original ResearchConceptsInjection drug usersHIV-seronegative patientsHIV-seropositive patientsDrug usersHIV infectionEarly syphilisProspective studyHuman immunodeficiency virus (HIV) infectionHigh-risk sexual activityPercent of HIVImmunodeficiency virus infectionMethadone maintenance treatmentDrug-using womenMultiple sex partnersDiagnosis of syphilisEarly syphilis incidenceFemale drug usersHIV seroconversionHIV seroconvertersMaintenance treatmentIncidence rateIndependent riskVirus infectionSyphilis incidencePatients
1995
Injection Drug Use and Human Immunodeficiency Virus Infection
Alcabes P, Friedland G. Injection Drug Use and Human Immunodeficiency Virus Infection. Clinical Infectious Diseases 1995, 20: 1467-1479. PMID: 7548494, DOI: 10.1093/clinids/20.6.1467.Peer-Reviewed Original ResearchConceptsSurveillance case definitionHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionDrug usersCase definitionInjection drugsVirus infectionPrevention (CDC) surveillance case definitionDiagnosis of AIDSInjection drug useInjection drug usersHigh mortality rateHIV diseaseHIV infectionDrug injectorsMortality rateDrug useNew casesNatural historyDisease controlAIDSDiagnostic facilitiesAIDS epidemicInitial epidemicLack of advocates
1994
Maturity of human immunodeficiency virus infection and incubation period of acquired immunodeficiency syndrome in injecting drug users
Alcabes P, Muñoz A, Vlahov D, Friedland G. Maturity of human immunodeficiency virus infection and incubation period of acquired immunodeficiency syndrome in injecting drug users. Annals Of Epidemiology 1994, 4: 17-26. PMID: 7911376, DOI: 10.1016/1047-2797(94)90038-8.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeBaltimoreCD4-Positive T-LymphocytesCohort StudiesConfidence IntervalsHIV InfectionsHIV SeroprevalenceHomosexualityHumansIncidenceLeukocyte CountLife TablesMaleModels, StatisticalNew York CityPlatelet CountRegression AnalysisSubstance Abuse, IntravenousSurvival RateTime FactorsConceptsHIV infectionDrug usersImmunodeficiency syndromeMedian timeCombined cohortHomosexual menHuman immunodeficiency virus (HIV) infectionHuman immunodeficiency virus (HIV) epidemicPercent of CD4Immunodeficiency virus infectionIncident HIV infectionProduct-limit methodMarkers of maturityHIV incubation distributionsPlatelet countVirus infectionLarge cohortSeroconversionCohortInfectionConfidence intervalsIncubation distributionAIDSVirus epidemicPopulation groupsLaboratory markers and the risk of developing HIV-1 disease among injecting drug users
Alcabes P, Selwyn P, Davenny K, Hartel D, Buono D, Schoenbaum E, Klein R, Friedland G. Laboratory markers and the risk of developing HIV-1 disease among injecting drug users. AIDS 1994, 8: 107-116. PMID: 7912083, DOI: 10.1097/00002030-199401000-00016.Peer-Reviewed Original ResearchConceptsCD4 lymphocyte countHIV-1-related outcomesLow CD4 lymphocyte countCD4 lymphocyte numbersPyogenic bacterial infectionsHIV-1 diseaseLymphocyte countLaboratory markersLymphocyte numbersClinical eventsAIDS diagnosisRelative riskDrug usersBacterial infectionsHIV-1-associated diseaseBeta 2M levelsSerum beta 2M levelsDifferent laboratory markersMultiple constitutional symptomsAIDS riskMethadone treatment programsPredictors of progressionHIV-1 infectionLow platelet countLower leukocyte counts